Bioservo: Commercialization progress - Redeye

Redeye saw results that did not represent a significant deviation from the expectations. The sales were up 58%, with costs trending downward. The deliveries of Carbonhand have started, and interest looks pretty high from different stakeholders. The earlier-than-expected US progress with the FDA registration is a clear positive. We only change our estimates slightly: however, the financing need adds another share issue of SEK 30 m, creating a dilution effect. We lower our Base case to SEK 3.3 per share from SEK 5 per share.

Länk till analysen i sin helhet: https://www.redeye.se/research/896982/bioservo?utm_source=finwire&utm_medium=RSS